Using a Revenue DCF model with operating margin convergence from 0.7% to a target of 13.2% over 5 years, discounted at a WACC of 7.3%, Cellyan Biotechnology Co., Ltd (HKPD) has an intrinsic value of $7.57 per share (range: $1.27 – $34.42).
Using a Revenue DCF model with operating margin convergence from 0.7% to a target of 13.2% over 5 years, discounted at a WACC of 7.3%, Cellyan Biotechnology Co., Ltd (HKPD) has an intrinsic value of $4.26 per share (range: $0.41 – $20.33).
Using the industry peer median EV/Revenue multiple (trailing + forward), Cellyan Biotechnology Co., Ltd (HKPD) has a fair value of $1.54 based on 9 comparable companies in the Medical - Pharmaceuticals industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Cellyan Biotechnology Co., LtdHKPD | 6 | 0.4x | — |
| Freightos Limited Ordinary shares | 106 | 3.2x | 3.2x |
| New Century Logistics (BVI) Limited | 44 | 7.8x | — |
| PS International Group Ltd. | 23 | 0.2x | — |
| Universal Safety Products, Inc. | 14 | 0.7x | 0.3x |
| Art's-Way Manufacturing Co., Inc. | 13 | 0.9x | — |
| Ten-League International Holdings Limited Ordinary Shares | 11 | 0.9x | — |
| VerifyMe, Inc. | 10 | 0.4x | 0.3x |
| Lakeside Holding Limited | 6 | 0.4x | — |
| Addentax Group Corp. | 3 | 6.0x | — |
| Industry Median | 0.9x | 0.3x | |
| (*) Revenue | 20 | ||
| = Enterprise Value | 17 | ||
| (-) Net Debt | 2 | ||
| Equity Value | 16 | ||
| (/) Outstanding shares | 10 | ||
| Fair Price | $2 | ||
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.